TrialBJU international2015

Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.

Katharine N Sourbeer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.